CLINICAL TRIAL
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Impact of minimum point dose on local control and toxicity in T3-4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy.

Background: We aim to explore the relationship between minimum point dose (Dmin) to the primary gross tumor volume (GTV_P) and local control in treating T3-4 nasopharyngeal carcinoma (NPC).

Methods: Ninety-six non-metastatic T3-4 NPC patients were enrolled between January 2009 and November 2013. Intensity-modulated radiation therapy (IMRT) plus docetaxel, cisplatin and fluorouracil (TPF) chemotherapy was administered. The prescribed dose was 66-70.4 Gy to the GTV_P while maintaining all the critical neurologic organs within dose constraints.

Results: The local response rate was 88.6% after induction chemotherapy. With a median follow-up of 48.5 months, the 3-year local failure-free survival (LFFS) and overall survival (OS) rates were 92.4% and 89.6%, respectively. The average Dmin to the GTV_P was 59.4 Gy (range, 48.3-70.4 Gy). Additionally, 54.0 Gy was identified as the optimal cut-off Dmin to the GTV_P, and the Dmin ≥54.0 Gy group had a better local complete response rate after IMRT (52.4% vs. 81.3%, χ2 = 7.335, P = 0.007), a better 3-year LFFS (95.9% vs. 78.4%, P = 0.005) and a better OS (93.3% vs. 75.9%, P = 0.003). Furthermore, a multivariate analysis found the Dmin to the GTV_P ≥54.0 Gy to be prognostically important for LFFS and OS. One patient (1%) developed asymptomatic temporal lobe necrosis, but no other neurological dysfunctions were observed.

Conclusions: For T3-4-stage NPC treated with IMRT plus TPF chemotherapy, excellent local control with few late toxicities was achieved. A Dmin ≥54.0 Gy to the GTV_P may confer better local control. New ways to increase the Dmin to the GTV_P as far as possible without increasing late toxicities are urgently required.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app